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Summary The acquisition of drug-resistant tumour cells is the main problem in the medical treatment of a range of malignant diseases. In
recent years, three new classes of anti-cancer agents, each with a novel mechanism of action, have been brought forward to clinical trials.
These are the topoisomerase (topo 1) poisons topotecan and irinotecan, which are both camptothecin derivatives, the taxane tubulin
stabilizers taxol and taxotere and, finally, the antimetabolite gemcitabin, which is active in solid tumours. The process of optimizing their use
in a combination with established agents is very complex, with numerous possible drug and schedule regimens. We describe here how a
broad panel of drug-resistant small-cell lung cancer (SCLC) cell lines can be used as a model of tumour heterogeneity to aid in the selection
of non-cross-resistant regimens. We have selected low-fold (3-1Ox) drug-resistant sublines from a classic (NCI-H69) and a variant (OC-NYH)
SCLC cell line. The resistant cell lines include two sublines with different phenotypes towards alkylating agents (H69/BCNU and NYH/CIS),
two sublines with different phenotypes against topo I poisons (NYH/CAM and NYH/TPT) and three multidrug resistant (MDR) sublines
(H69/DAU, NYH/VM, and H69NP) with combinations of mdrl and MRP overexpression as well as topoisomerase 11 (topo 11) down-regulation
or mutation. Sensitivity to 20 established and new agents was measured in a standardized clonogenic assay. Resistance was highly drug
specific. Thus, none of the cell lines was resistant to all drugs. In fact, all resistant cell lines exhibited patterns of collateral sensitivity to various
different classes of drugs. The most intriguing pattern was collateral sensitivity to gemcitabin in two cell lines and to ara-C in five drug-
resistant cell lines, i.e. in all lines except the lines resistant to topo poisons. Next, all sensitivity patterns in the nine cell lines were compared
by correlation analysis. A high correlation coefficient (CC) for a given pair of compounds indicates a similar pattern in response in the set of
cell lines. Such data corroborate the view that there is cross-resistance among the drugs. A numerically low coefficient indicates that the two
drugs are acting in different ways, suggesting a lack of cross-resistance between the drugs, and a negative correlation coefficient implies that
two drugs exhibit collateral sensitivity. The most negative CCs (%) to the new drug leads were: taxotere-carmustine (BCNU) (-75),
taxol-cisplatin (-58), ara-C-taxol (-25), gemcitabin-doxorubicin (-32), camptotecin-VM26 (-41) and topotecan-VP16 (-17). The most
negative correlations to the clinically important agent VP-16 were: cisplatin (-70); BCNU (-68); camptothecin (-38); bleomycin (-33),
gemcitabin (-32); ara-C (-21); topotecan (-17); melphalan (-3); and to the other main drug in SCLC treatment cisplatin were: doxorubicin
(-70); VP-16 (-70); VM-26 (-69); mAMSA (-64); taxotere (-58); taxol (-58). Taxol and taxotere were highly correlated (cross-resistant) to VP-
16 (0.76 and 0.81 respectively) and inversely correlated to cisplatin (both -0.58). Similarly, camptothecin and topotecan were correlated to
cisplatin but inversely correlated to VP-16 and other topo 11 poisons. From the sensitivity data, we conclude that collateral sensitivity and lack
of cross-resistance favours a cisplatin-taxane or topo 1-topo 11 poison combination, whereas patterns of cross-resistance suggest that
epipodophyllotoxin-taxane or topo poison-cisplatin combinations may be disadvantageous.
Keywords: clonogenic assay; multidrug resistance; resistance to alkylating agents and topoisomerase poisons; collateral sensitivity;
new drug combinations
The treatment ofsmall-cell lung cancer (SCLC) is currently under- tumour development furthers the idea of using families of wild-
taken by a few drug types, which include alkylating agents such as type and resistant cells in an attempt to model the clinical situation
cisplatin and cyclophosphamide, topoisomerase II (topo II) and reflect the known tumour heterogeneity. Several investigators
poisons such as etoposide (VP-16) and doxorubicin, and tubulin- have studied the drug sensitivity of panels of SCLC cell lines in
destabilizing drugs such as vincristine. The final treatment failure vitro. Some investigators have not been able to demonstrate any
in the great majority of patients despite primary response rates of differences in the sensitivity patterns to different drug types with
approximately 80% is considered to be due to the emergence of different mechanisms of action, such as etoposide (VP-16) and
drug-resistant cell populations. The clonal evolution hypothesis of cisplatin, in large panels of wild type cell lines. Such data suggest
that treatment failure is due to the presence of a pan-resistant
Received8July 1996 phenotype (Tsai et al, 1990). This finding disagrees with the notion
FRevised7October1996 that resistance mechanisms are drug-type specific. Also, some
Accepted 8 October 1996 investigators have described cell lines with a very high sensitivity
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primary treatment ofSCLC is as the result ofthe initial presence of
a multidrug-sensitive phenotype (Giaccone et al, 1992). If it is
correct that the primary drug sensitivity is a result of hypersensi-
tivity and that drug resistance is due to the loss of a programmed
cell death or to the loss of other common pathways for cell death,
the search for new active drugs would definitely appear to be hope-
less. In contrast to these two extremes, i.e. the ultimate presence of
a pan-resistant phenotype or the initial presence of a multidrug-
sensitive phenotype, we and others have found differential sensi-
tivity patterns when investigating the cytotoxicity of various
compounds in panels ofcell lines (Schabel et al, 1983; Jensen et al,
1992, 1993a; Weinstein et al, 1992; Koutsoukos et al, 1994).
Accordingly, one way of circumventing current drug resistance
would be to develop new drug types that can act on cellular targets
other than those already in use. In recent years, three new classes of
anti-cancer agents each with a novel mechanism of action have
been brought forward to clinical trials. These are the topoisomerase
I (topo I) poisons topotecan and irinotecan, which are both camp-
tothecin derivatives, the taxane tubulin stabilizers taxol and
taxotere and finally the antimetabolite gemcitabin, which is active
in solid tumours. In order to supply knowledge as to appropriate
combinations of standard drugs with these new drugs, we have
performed a preclinical evaluation of drug combinations using a
standardized clonogenic assay system on two wild type SCLC cell
lines, NCI-H69, a classic type, and OC-NYH, which belongs to the
variant type, and their drug-resistant sublines as a preclinical
model of SCLC. Our results indicate that drug resistance is indeed
drug specific as none of our cell lines are resistant to all drugs.
From the sensitivity data we conclude thatcollateral sensitivity and
lack ofcross-resistance favours a cisplatin-taxane ortopo 1-topo II
poison combination, whereas patterns of cross-resistance suggest
that epipodophyllotoxin-taxane or topo I poison-cisplatin may be
inappropriate.
Table 1 DNA content, plating efficiency, relation to chemotherapy and
mechanism of resistance
Cell line Dl PE (%) Prior Mechanism of
therapy resistance
NCI-H69 0.90 12 Yes
H69/DAU 0.87 12 mdrl overexpression,
Topo II down-regulation
69NP 0.82 13 MRP and mdrl overexpression,
normal topo 11 level but
extranuclear localization
H69/BCNU ND 20 06-methylguanine-DNA-
methyltransferase overexpression
OC-NYH 1.39 27 No
NYHNM 1.29 30 Topo II down-regulation
NYH/TPT 1.10 27 Topo down-regulation,
topo 11 up-regulation
NYH/CAM 1.16 31 No topo 11 change,
unknown downstream change
NYH/CIS 1.14 30 Glutathione overexpression
Dl, DNA index; PE, plating efficiency at approximately 3000 colonies; ND, not
determined. OC-NYH and its sublines grow as monolayers and NCI-H69 and
its sublines grow in suspension.
MATERIALS AND METHODS
Drugs
06-benzylguanine was kindly supplied by Dr Robert C Moschel,
Frederick Cancer Research and Development Center, Frederick,
MD, USA. 06-benzylguanin was dissolved in dimethyl sulphoxide
(DMSO). Melphalan (Wellcome) was dissolved in hydrochloric
acid with ethanol and further diluted in propyleneglycol phosphate
buffer; m-AMSA (Parke-Davis) was delivered in N,N-dimethylac-
etamid solution and further diluted in acid lactose; and ara-
C (cytosine arabinoside) (Upjohn) was dissolved in benzyl
alcohol. All the solvents used were dispensed by the producers.
Doxorubicin (Farmitalia Carlo Erba Pharmacia), bleomycin
(Lundbeck), hydroxyurea (Bristol-Myers Squibb), mitomycin C
(Kyowa), gemcitabin (Lilly), vincristine (Lilly) and topotecan
(SmithKline Beecham) were dissolved in sterile water. Vindesine
(Lilly) was dissolved in isotonic sodium chloride. Camptothecin
(Sigma), taxotere (Rhone-Poulenc Rohrer) and taxol (Bristol-
Myers Squibb) were dissolved in DMSO. BCNU (carmustine)
(Bristol-Myers Squibb) was dissolved in 10% (v/v) ethanol in
sterile water. Mitoxantrone (Lederle), VP-16 (etoposide) (Bristol-
Myers Squibb), VM-26 (teniposide) (Bristol-Myers Squibb) and
cisplatin (Bristol-Myers Squibb) were in solution for infusion. The
drugs were diluted with tissue culture medium to 300 x final
concentrations, partitioned into multiple aliquots, frozen on
ethanol-dry ice and stored at -80°C. Just before culture applica-
tion, the contents of the frozen vials were thawed and mixed. As
described in Jensen et al (1993a), the cytotoxic stability of the
frozen drugs stored at -80°C for 30-40 days was checked by
comparing with freshly diluted drug in a clonogenic assay. All
drugs were checked in this setting.
Cell lines
The human SCLC cell lines used are the classic type NCI-H69
(Carney et al, 1985) and the variant type OC-NYH (de Leij et al,
1985). The multidrug-resistant (MDR) SCLC cell lines used were
H69/DAU, H69/VP and OC-NYH/VM, selected for resistance to
daunorubicin, VP-16 and VM-26 respectively. H69/DAU is a clas-
sical MDR cell line with P-glycoprotein in the cell membrane
(Jensen et al, 1989) and a reduced level of topo 11a; NYHIVM is
resistant because of reduced topo-IIa activity and content (Jensen
et al, 1993b); and H69NVP exhibits the multidrug resistance
protein (MRP) (Brock et al, 1995), P-glycoprotein (Jensen et al,
1992) and a cytoplasmatic distribution of the target enzyme DNA
topo II, presumably due to a mutation in a nuclear localization
sequence (unpublished observation). The topotecan-resistant
NYH/TPT cells exhibit a 50% reduction in topo I content and a
doubling of the topo II level (Sorensen et al, 1995), whereas the
camptothecin-selected NYH/CAM cells have an, until now, unex-
plained mechanism of resistance involving an unchanged topo I
level and catalytic activity and a slightly increased topo II content
(manuscript in preparation). NYH/CIS and H69/BCNU, selected
for cisplatin and BCNU resistance, respectively, are characterized
in this report. Resistant cell lines were grown in vitro without drug
for a minimum of 5 days before testing. All cell lines were main-
tained at 37°C in RPMI 1640 with 10% fetal calf serum in a
humidified atmosphere with 7.5% carbon dioxide. At regular
intervals, the panel of cell lines was re-established from frozen
subcultures to reduce or avoid sensitivity drifting. The cell lines
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Figure 1 The relative sensitivity to 20 anti-cancer agents in the
multidrug-resistant cell lines H69/DAU (A) and H69NP (B)
compared with the parental line NCI-H69 and in NYH/VM
compared with the parental line OC-NYH (C). For a given pair
of cell lines the mean LD, was set to 100% for each drug. The
plot shows the LD50 values of each cell line relative to mean
LD50 values. Results from at least three experiments. Bars
represent two s.e.m. A star denotes the sensitivity of the
resistant cell line and a circle the wild type line. If, for a given
drug, a star is above a circle the resistant cell line exhibits
cross-resistance to the drug; if a star is below a circle, the
resistant cell line exhibits collateral sensitivity to the drug. Five
different targets or mechanisms of action are denoted on the
top of the figure: tubulin, topo 11, topo 1, alkylating and
antimetabolites. Aclarubicin and bleomycin do not fit in with
these five drug types. 0, wild-type cell line. *Resistant subline
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Figure 2 The relative sensitivity to 20 anti-cancer agents in the cell lines
H69/BCNU and NYH/CIS selected for resistance to the alkylating agents
BCNU and cisplatin. A compares H69/BCNU with H69 and B shows
NYH/CIS compared with NYH. For a given pair of cell lines, the mean LD50
was set to 100% for each drug. The plot shows the LD50 values of each cell
line relative to mean LD50 values. Results from at least three experiments.
Bars represent two s.e.m. See legend to figure 1
were free of mycoplasm contamination. DNA content (Vindel0v
and Christensen, 1990), plating efficiency, relation to chemo-
therapy, mechanism ofresistance and growth behaviour in vitro of
the cell lines used are described in Table 1.
Cellular glutathione content
Glutathione conjugation represents a major detoxification reaction
in the deactivation of xenobiotics. Cells with resistance towards
alkylating agents often exhibit an increased level of glutathione.
DTNP (5,5'-dithio-bis(2-nitrobenzoic acid), NADPH (,-nicoti-
namide adenine dinucleotide phosphate), glutathione reductase,
glutathione, imidazole and imidazole hydrochloride were all from
Sigma. 2-4x106 cells were washed in ice-cold phosphate-buffered
saline (PBS) and collected by centrifugation at 3000 r.p.m. for 3
min at 4°C. Protein was precipitated by adding 500 ,ul of20% ice-
cold trichloroacetic acid (TCA). This was mixed vigorously and
incubated at 4°C for 15 min and extracts were neutralized to pH
7.0 by adding 400 ,ul of2.1 M potassium hydroxide-l M imidazole
base-0.5 M potassium chloride and kept on ice for 15 min. The
mixture was centrifugated at 10 000 r.p.m. for 2 min at 4°C. The
pellet was saved for protein determination. The supernatant was
analysed for total glutathione content through enzyme recycling
under conditions similar to those described by Tietze (1969).
Modulation of sensitivity with 06-benzylguanine
One well-characterized mechanism ofdrug resistance to alkylating
agents involves the DNA repair protein of 06-methylguanine-
DNA methyltransferase, which removes alkyl adducts from the
lites 06-position ofguanine in DNA (Dolan etal, 1990). Cells in single-
cell suspension were incubated for 1 hour with O6-benzylguanine
(20 uM) and were then exposed for 2 hours to a range of BCNU
concentrations; the cells were subsequently washed in PBS x 2
and plated in the presence of 20 uM O6-benzylguanine on top of a
feeder layer, as explained below in the clonogenic assay section.
Clonogenic assay
We have previously demonstrated that the comparison ofeffects of
different drugs in a cell line is more reliable when the drugs are
compared in simultaneous experiments on the same batch ofcells.
To obtain more dose-response curves on one batch of cells, we
therefore developed an automatic colony counter (Jensen et al,
1993a). In each experiment, all 20 drugs (three concentrations of
each, all plated in triplicate) and six control triplicates were tested
on the same batch ofcells. Single-cell suspensions (1-4 x 104 cells
ml') in RPMI 1640 supplemented with 10% fetal calf serum were
plated in soft agar on afeeder layercontaining sheep red blood cells
(Roed et al, 1987) in 35-mm Petri dishes with the desired drug
concentrations (continuous incubation). The number of cells were
adjusted to obtain 2000-3000colonies in thecontrol dishes. Solvent
concentrations never exceeded 1% and had no influence on the
plating efficiency. Plating was carried out within 1 h as the intraex-
perimental variation in plating efficiency of the controls exceeded
10% in more prolonged experiments. After 14-21 days, the
colonies were counted on the image analysis system. Colonies
largerthan 50 gm in diameterwere regarded as positive. Thecolony
counter was interfaced with a computer and data were stored and
analysed through use of SAS software. The dose reducing the
number ofcolonies to 50% of control (LD50) was determined from
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7.0); ACLA (0.0037, 0.012, 0.025); DOX (0.026, 0.074, 0.13);
MELPHAL (0.33,0.9,1.6); ARAC (0.025,0.075,0.15); BLEOMY
(0.02, 0.07, 0.14); CAMPTO (0.0014, 0.0028, 0.0056); CISPT
(0.33,0.66,1.3); HYDREA(39,79,237); MAMSA (0.05,0.1,0.3);
MITO (0.014, 0.045, 0.09); MITOMY (0.009, 0.021, 0.06);
VINCRI (0.001, 0.002, 0.004); VINDES (0.001, 0.002, 0.003);
VM26 (0.02, 0.05, 0.1); VP16 (0.125, 0.3, 0.6); TAXOL (0.0007,
0.0021, 0.0042); TAXOTERE (0.0002,0.0004,0.0011); TOPOTE
(0.0022, 0.0066, 0.013); GEMCIT (0.0017, 0.0033, 0.017). When
the calculatedLD50 values were above three times thehighest tested
concentration, the LD50 was assigned this value (i.e. 3 x LD90 on
OC-NYH). Patterns in sensitivity were studied by correlation
analysis using rank orders ofsensitivity with allpossiblepairings of
the 20 agents.
At least thee experiments were included for each drug and cell
line. Computations used correlation coefficients calculated as
Spearman rank-order correlations.
RESULTS
Sensitivity patterns in resistant cell lines
________________________ Drug cytotoxicity was determined in a clonogenic assay as
described in Materials and methods. The relative sensitivity of the
0 2 4 6 8 10 12 14 16 wild-type cell line NCI-H69 compared withH69/DAU is shown in
BCNU (rg ml-') Figure IA. H69/DAU is a multidrug-resistant cell line exhibiting
ose-response curves based on the clonogenic assay P-glycoprotein. Note that there is collateral sensitivity (CS) to
ing the effect of O6-benzylguanine on the sensitivity to BCNU on cisplatin as well as to ara-C and to the ara-C analogue gemcitabin.
39/BCNU cell lines. A non-toxic dose of 06-benzylguanin almost . .
restores sensitivity to BCNU in H69/BCNU to wild type levels In fact, the collateral sensitivity to ara-C iS eightfold. Furthermore.
- -), whereas the modulator has no effect on BCNU sensitivity in although there is no cross-resistance to camptothecin, there is
e line NCI-H69 (the two curves to the left). Bars represent two statistically significant cross-resistance (CR) to topotecan in
triplicate cultures H69/DAU. Similar data have been published previously (Chen et
al, 1991; Hendriks et al, 1992). As expected from other studies,
g concentration points in linear regression analysis on there is also cross-resistance to taxol and taxotere in this P-glyco-
ically transformed response data (Jensen et al, 1993a). protein-positive cell line.
concentrations chosen approximated to LD10, LD50 and In Figure iB, NCI-H69 is compared with H69NVP cells which
ined on cell line OC-NYH from dose-response curves in were selected for etoposide (VP-16) resistance. H69/VP exhibits
Experiments and were as follows (,UM): BCNU (0.9, 2.3, the multidrug resistance protein (MRP) as well as P-glycoprotein
Table 2 Summary of sensitivity patterns to 20 anti-cancer agents in seven drug-resistant cell lines. A blank field signifies cross-resistance, 0 signifies
non-cross-resistance and CS collateral sensitivity, i.e. compared with the parental cell line, the cells have become significantly more sensitive to the drug
H69/DAU H69NP H69/BCNU NYHNM NYH/CIS NYH/TPT NYH/CAM
Vindesine CS 0 0 0
Vincristine CS 0 0 0 0
Taxol CS 0 0
Taxotere CS 0 0
Doxorubicin CS 0 0 CS
Mitoxantrone 0 CS 0 0
m-AMSA CS 0 0 0
VP-16 CS 0 0 CS
VM-26 CS CS CS CS
Aclarubicin 0 0 0 0 0
Camptothecin 0 0 0 0
Topotecan 0 0 0
Mitomycin 0 CS CS 0 0
Melphalan 0 0 0 0
BCNU 0 0 0 0 0
Cisplatin CS CS 0 0
Bleomycin 0 0 0 0 0 0 0
Ara-C CS CS CS CS CS 0 0
Gemcitabin CS 0 CS 0 0 0 0
Hydrea 0 CS 0 0 0 CS
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Table 3 Correlation analysis on rank order of sensitivity with all possible pairings of the six new drug leads to the 19 other anti-cancer agents. Correlation
coefficients (%) were obtained in two wild type lines and seven drug-resistant sublines. A positive correlation indicates that the sensitivity patterns overlap, i.e.
the drugs are effective on the same clones (cross-resistance); a negative correlation signifies that the drugs exhibit opposite patterns (collateral sensitivity)
Gemcitabin ara-C Taxotere Taxol Topotecan Camptothecin
Vindesine 14 2 52 59 51 -2
Vincristine 13 -2 80 76 13 -4
Taxol -24 -25 76 28 -23
Taxotere -9 -5 76 21 -33
Doxorubicin -32 -13 75 77 -11 -29
Mitoxantrone 8 11 83 68 11 -18
mAMSA -30 -24 88 76 5 -32
VP-16 -32 -21 81 76 -17 -38
VM-26 -25 -22 77 69 -14 -41
Aclarubicin -4 -12 63 59 46 22
Camptothecin 38 26 -33 -23 69
Topotecan 33 3 21 28 69
Mitomycin 27 33 59 41 45 40
Melphalan 25 -22 7 20 81 65
BCNU -13 -13 -75 -52 4 5
Cisplatin 41 16 -58 -58 33 55
Bleomycin 29 -3 -35 -14 6 8
Ara-C 60 -5 -26 3 26
Gemcitabin 60 -9 -24 33 38
Hydrea 10 35 43 9 32 33
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Figure 4 Sensitivity patterns to camptothecin, VP-16, cisplatin and taxol on
the two wild-type and seven resistant SCLC cell lines. The results are
depicted as the mean relative LD50values from at least three experiments and
the cell lines are sorted by increasing sensitivity to cisplatin. Bars are plus one
s.e.m. CIS, NYH/CIS; TPT, NYH/TPT; CAM, NYH/CAM; BCNU, H69/BCNU;
H69, NCI-H69; NYH, OC-NYH; VM, NYHNM; VP, H69NP; DAU, H69/DAU
and, in addition, immunohistochemistry demonstrates a clearcyto-
plasmatic localization ofthe etoposide target enzymetopo-lIIa(not
shown). Thus, three different mechanisms of etoposide resistance
are simultaneously present in this cell line. In spite of this, the
etoposide resistance is not several logs but only a factor ofthree to
four as seen in Figure lB. H69/VP exhibits collateral sensitivity to
mitomycin and hydrea and, similar to the P-glycoprotein positive
H69/DAU, the subline also exhibits collateral sensitivity to
cisplatin and ara-C. In contrast to H69/DAU, however, there is no
cross-resistance to topotecan in this line. This could be explained
by the fact that the level of P-glycoprotein in H69/VP is much
lower than in H69/DAU (Brock et al, 1995).
In Figure IC, the wild-type cell line OC-NYH is compared with
NYHNVM. NYH/VM was selected for teniposide (VM-26) resis-
tance, the cell line exhibits a two- to threefold reduced topo-II
activity and content ofboth the aand0 form (Jensen et al, 1993 b).
Observe a slight cross-resistance to taxol and taxotere but no cross-
resistance to vincristine or vindesine and no resistance to
topotecan. Also, this subline exhibits collateral sensitivity to ara-C.
In Figure 2A, H69 is compared with H69/BCNU. H69/BCNU
is almost exclusively resistant to BCNU with a trend towards
cross-resistance to topotecan. Also, this subline exhibits a collat-
eral sensitivity to ara-C.
In Figure 2A, H69 is compared with H69/BCNU. H69/BCNU is
almost exclusively resistant to BCNU with a trend towards cross
resistance to melphalan and cisplatin. Curiously, the cell line
exhibits collateral sensitivity to a number of anti-cancer agents,
not only to all topo II-targeting agents but also the tubulin-
targeting drugs and ara-C. The cell line was studied in the presence
of 06-benzylguanine. As seen in Figure 3, 06-benzylguanine
completely restores the sensitivity to BCNU in H69/BCNU to the
wild type level. For comparison, 06-benzylguanine had no effect
on the sensitivity to BCNU in H69 cells. It is still unresolved
whether the increased 06-methylguanine-DNA methyltransferase
expression is involved in the pattem of multiple collateral sensi-
tivity to other agents.
British Journal ofCancer(1997) 75(6), 869-877
0
0CancerResearch Campaign 1997Sensitivitypattems in resistantSCLC 875
In Figure 2B OC-NYH is compared with NYH/CIS. NYH/CIS
exhibits cross-resistance to all alkylating agents. In addition there
is cross-resistance to hydrea, to topo I poisons and slight cross-
resistance to the taxanes. There is no cross-resistance to topo II
poisons or ara-C-gemcitabin; in fact, there is collateral sensitivity
to VM-26 and ara-C. In three experiments, glutathione levels were
1.4- to 2.4-fold (median 1.6-fold) higher in NYH/CIS than in
NYH. Median glutathione levels in NYH/CIS and NYH were 0.85
and 0.5 nmol 10- cells respectively. Accordingly, an increased
level of glutathione in NYH/CIS is one plausible mechanism of
resistance to cisplatin, BCNU and melphalan.
In Table 2, the sensitivity patterns of all resistant sublines are
summarized, including the cell lines selected with the topo I
poisons NYH/TPT and NYH/CAM.
In Figure 4, the cell lines are ranked according to sensitivity to
cisplatin. As seen at the bottom of the figure, the pattern to taxol is
almost the reverse ofthe pattern to cisplatin, i.e. cell lines resistant to
the one drug are sensitive to the other. On the top panel is shown the
patterns to camptothecin and etoposide. The pattern to camptothecin
resembles the pattern to cisplatin and is the reverse ofetoposide.
To compare the possible drug pairings, we performed a correla-
tion analysis using rank orders of sensitivity with all possible pair-
ings ofthe 20 agents. A high correlation coefficient (CC) for a given
pair of compounds indicates a similar pattern in response in the set
ofcell lines. Such data corroborate the view that there is cross-resis-
tance among the drugs. A numerically low coefficient indicates that
the two drugs are acting in different ways suggesting a lack ofcross-
resistance between the drugs, and finally a negative correlation coef-
ficient implies that two drugs exhibit collateral sensitivity. Table 3
shows the Spearman correlation coefficients (CCs) to gemcitabin,
ara-C, taxotere, taxol, topotecan and camptothecin. The most nega-
tive CCs to the new drug leads were: taxotere/BCNU (-75),
taxol-cisplatin (-58), ara-c-taxol (-25), gemcitabin-doxorubicin
(-32), camptothecin-VM26 (-41), topotecan-VP16 (-17).
In SCLC, the two most widely used drugs are etoposide and
cisplatin, and we therefore ranked their CCs to the other 19 drugs
as follows.
(a) Ranking the correlations to VP-16:
cisplatin (-70) BCNU (-68) camptothecin (-38) bleomycin
(-33) gemcitabin (-32) cytosine arabinoside (-21) topotecan
(-17) melphalan (-3) hydroxyurea (14) mitomycin C (26)
vindesine (32) aclarubicin (50) vincristine (63) mitoxantrone
(73) taxol (76) taxotere (81) m-AMSA (89) doxorubicin (92)
tenoposide (97)
(b) Ranking the correlations to cisplatin:
doxorubicin (-70) etoposide (-70) teniposide (-69) m-AMSA
(-64) taxotere (-58) taxol (-58) mitoxantrone (-54) vincristine
(-50) aclarubicin (-44) vindesine (-35) mitomycin C (-2) hydrea
(5) ARAC (16) melphalan (29) bleomycin (32) topotecan (33)
gemcitabin (41) camptothecin (55) carmustine (68)
DISCUSSION
Treatment of SCLC often includes either the combination of CAV,
i.e. cyclophosphamide + doxorubicin + vincristine, or PE, i.e.
cisplatin + etoposide. The latter is considered by many oncologists to
be the golden standard in the treatment of SCLC today. It is notable
that two ofthree MDR cell lines exhibit collateral sensitivity (CS) to
cisplatinum and that NYH/CIS exhibits CS to teniposide (VM-26 in
Table 2). This inverse correlation has been a puzzle for a long time
(Tan et al, 1987). The phenomenon is even more striking when
turning to the comparison of variations in sensitivity. Thus, in this
study, the sensitivity pattern to cisplatin is inversely correlated to the
patterns of etoposide and teniposide (correlation coefficients -69%
and -70% respectively) (Figure 4). It has been suggested that DNA
topo II is involved in DNA repair; accordingly, a low topo II content,
which would convey resistance to topo II poisons, would diminish
DNA repair capacity and lead to hypersensitivity to cisplatin and vice
versa. This hypothesis was recently tested in a cell line transfected to
overexpress topo II and, indeed, this line exhibited increased sensi-
tivity to topo II poisons and decreased sensitivity to cisplatin (Eder et
al, 1995). CAV or PE regimens give remissions in 80% of patients
but are obviously seldom sufficient to cure the patients, and new
drugs with activity in the doubly resistant cell populations are
urgently needed. Thus, the identification of drugs with effect in the
etoposide and cisplatin-resistant phenotype appears to be particulary
important. In recent years, three new classes of anti-cancer agents
each with a novel mechanism ofaction have been brought forward to
clinical trials. These are the antimetabolite gemcitabin, which is
active in solid tumors, the topo I poisons topotecan and irinotecan,
which are both camptothecin derivatives and, finally, the taxane
tubulin stabilizers taxol and taxotere.
Gemcitabin and ara-C
The sensitivity pattern to ara-C is inversely correlated for the topo
II poisons doxorubicin (CC - 12) and etoposide (CC-2 1). In addi-
tion, all the MDR cell lines that are cross-resistant to topo II
poisons exhibit collateral sensitivity to ara-C. Thus, the MDR cells
have become more sensitive to ara-C than their parental wild type
cells. This clearly suggests that it might be ofbenefit to combine a
topo II poison and ara-C. Interestingly, the 3+7 combination ofthe
topo II poison daunorubicin and ara-C is very important in the
treatment of acute myeloblastic leukaemia (Keating et al, 1993).
Unfortunately, ara-C is not clinically active in SCLC but the ara-C
analogue, gemcitabin, has demonstrated response rates of 20% in
non-small-cell lung cancer (Abratt et al, 1994; Anderson et al,
1994) and 27% in SCLC (Cormier et al, 1994). However, it is
unfortunate that gemcitabin does not exhibit a sensitivity pattern
identical to that of ara-C. As seen in Table 2, five of the resistant
sublines exhibit collateral sensitivity (CS) to ara-C whereas only
two of the lines exhibit CS to gemcitabin. In accordance with this,
the ara-C-gemcitabin correlation of only 60% also indicates some
difference between their mechanisms of action or their cellular
pharmacokinetics. As seen in Table 2, the topo I-resistant lines
NYH/TPT and NYH/CAM have unaltered sensitivity to ara-C
whereas the three MDR and the two alkylating resistant lines
exhibit CS. This suggests that a compound with activity in solid
tumours and with ara-C characteristics would be an extremely
interesting adjunct to the classic cisplatin-etoposide or cyclophos-
phamide-doxorubicin-vincristine SCLC treatment protocols.
Topo I poisons
There is a remarkable cross-resistance to camptothecin and
topotecan in NYH/CIS, suggesting that increased glutathione
levels may also lead to resistance to topo I poisons. Other explana-
tions such as altered topoisomerase I activity may be more plau-
sible, and we are currently measuring topoisomerase levels and
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activity in NYH/CIS. Similarly NYH/CAM and NYH/TPT exhibit
cross-resistance to cisplatin. From a clinical point of view, it is
worrying that resistance to camptothecin and topotecan may be
linked to cisplatin resistance; thus, topo I-directed drugs may not
be an independent adjunct to the standard cisplatin and etoposide
regimens in SCLC.
Several observations indicate that cellular resistance to topo I-
targeting drugs is associated with a decrease in enzymatic activity
caused by down-regulation and/or mutation of the topo-I gene
(Andoh et al, 1987; Kjeldsen et al, 1988; Sugimoto et al, 1990a;
Tanizawa and Pommier, 1992; Sorensen et al, 1995) Cells that are
resistant to camptothecin appear to depend to a greater extent than
wild-type cells upon topo II activity (Sugimoto et al, 1990b; Oguro
et al, 1990). This, in turn, can lead to collateral sensitivity to topo
1I-targeting agents (Sugimoto et al, 1990b). Thus, cells resistant
to topo I poisons are, in some cases at least, hypersensitive to
topo II poisons. In the present investigation, both NYH/CAM
and NYH/TPT exhibit collateral sensitivity to teniposide and
NYH/CAM also to etoposide and doxorubicin. Furthermore, resis-
tance towards topo- II poisons is frequently associated with
increased topo I level and/or sensitivity to camptothecin (Tan et al,
1989; Minato et al, 1990; Lefevre et al, 1991). We found no cross-
resistance to camptothecin in the MDR lines. Indeed, in all three
MDR lines, there is a trend towards collateral sensitivity to camp-
tothecin. Thus, studies on cell lines resistant to topo I or II poisons
have demonstrated a pattern ofcollateral sensitivity between these
two drug types, suggesting that a sequential administration of
these drugs would be beneficial. These results have made us
initiate a phase II clinical trial with a schedule of sequential
administration of topo I poison-platinum and a topo II
poison-platinum regimen in previously untreated SCLC patients.
Taxane plus platinum
The combination ofa taxane and a platinum derivative has demon-
strated high activity in a number of tumours, e.g. the well known
high activity of cisplatin plus taxol in the treatment of ovarian
carcinomas (McGuire et al, 1995). Also, this combination appears
very active in non-SCLC (Belani et al, 1995), and there are results
suggesting impressive activity in breast cancer (Gelmon, 1995). It
is therefore interesting that the comparison of patterns on our
panel of cell lines demonstrate inverse correlations between these
drug types (Figure 4 bottom). Thus, the correlation coefficients of
cisplatin-taxol and cisplatin-taxotere are both as low as -58%, i.e.
an inverse pattern similar to the pattern ofepipodophyllotoxin plus
platinum. Therefore, the combination of a taxane and platinum is
very promising because oftheir lack of mutual cross-resistance. In
addition, the combination of a taxane and the alkylating agent
BCNU appears very promising. BCNU-taxol and BCNU-taxotere
show CCs of-52% and -75% respectively. These figures compare
favourably with the etoposide-cisplatin correlation (-70%) and
could give support for a clinical trial.
In conclusion, the differential sensitivity patterns demonstrated
herein clearly support the notion that there is no cell line that alone
could represent the drug-resistant phenotype. In fact, all cell lines
exhibited patterns of collateral sensitivity to various different
classes of drugs. The analysis of the differential cytotoxicity
patterns and of patterns of collateral sensitivity enable combina-
tions of non-cross-resistant drugs and makes it possible to obtain
information about drug mechanism of action. This observation
agrees with results from the National Cancer Institute (NCI) in
vitro anti-tumour drug screen which showed that sensitivity data in
a panel ofdiverse cell lines can be used to predict drug mechanism
of action (Weinstein et al, 1992, Koutsoukos et al, 1994). Clearly,
none of the data above may be applied clinically without caution
and concern for the recognized gap between simple preclinical
models and the complicated clinical reality. But, although simpli-
fied, the model does provide information that we can use and test
in the design of new treatment protocols.
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ABBREVIATIONS
ACLA, aclarubicin (aclacinomycin A); DOX, doxorubicin;
ARAC, cytosine arabinoside (cytarabine); BCNU, carmustine;
BLEOMY, bleomycin; CISPT, cisplatin (diamminedichloroplat-
inum); CAMPTO, camptothecin; GEMCIT, gemcitabin; HYDREA,
hydroxyurea; NSCLC, non-small-cell lung cancer; MDR,
multidrug resistance; MITO, mitoxantrone; MELPHAL, melphalan;
MITOMY, mitomycin C; SCLC, small-cell lung cancer; TOPO,
topoisomerase; TOPOTE, topotecan; VINCRI, vincristine;
VINDES, vindesine; VP-16, etoposide; VM-26, teniposide
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